Enzyme composition for therapeutic management of muscle soreness

A muscle soreness, therapeutic technology, applied in the field of digestive enzymes, to relieve the symptoms of delayed onset muscle soreness, can solve the problems of limited effectiveness, limited efficacy and inconsistency

Pending Publication Date: 2019-08-23
SAMI LABS LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, absorption problems and disruption of enzymes in the gut can limit the effectiveness of traditional anti-DOMS enzyme (protease) therapies
Furthermore, the efficacy of these treatments is limited and inconsistent due to a lack of understanding of the exact mechanisms of DOMS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Enzyme composition for therapeutic management of muscle soreness
  • Enzyme composition for therapeutic management of muscle soreness
  • Enzyme composition for therapeutic management of muscle soreness

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Study Design

[0025] Product Description: It is "off-white to milky white powder of multi-enzyme complex". This multi-enzyme complex consists of amylase, protease, lipase, cellulase and lactase. Placebo capsules contained an equivalent weight of maltodextrin. No differences in colour, taste, texture or packaging were detected between the two products. The capsules are sealed in high-density polyethylene bottles of the same appearance as the desiccant. The composition of the multi-enzyme complex is given in Table 1.

[0026] Table 1. Compositional details of the multi-enzyme complex (DigeZyme) formulations

[0027]

[0028] Enzyme units are defined according to Food Chemical Codex (FCC), 5th Edition 2004. The National Academy Press Washington, D.C.

[0029] Ethics approval: Ethics approval was obtained from Sparsh Hospital, Advanced Surgery, #146, Infantry Road, Bangalore (according to gazette notification number F.28-10 / 45-H dated 21 December 1945 ...

Embodiment II

[0037] Example II: Procedure Followed:

[0038] Protocol for Inducing DOMS: Subjects were instructed to ingest study supplements and report to the site after 24 hours for baseline readings. After a 10-hour fast, heart rate and perceived exercise ratings were monitored at rest and every 5 minutes during exercise and recovery for 10 minutes. Participants installed a level motorized treadmill and warmed up at a voluntary pace (pace) for 5 minutes. After a 5-minute warm-up, the treadmill speed was increased until the heart rate reached 80% of the predicted maximum heart rate and was instructed to maintain this pace for 5 minutes. Adjust the treadmill level to 10% at this time and hold for 30 minutes. Subjects then completed a 5-minute active cool-down and a 5-minute seated passive recovery period at a self-selected stride. Subjects were restricted from any other physical activity 24 hours before and 72 hours after the exercise session.

[0039] Muscle soreness was quantified u...

Embodiment III

[0044] Embodiment III: Result:

[0045] Physical Characteristics: The population is generally healthy, with no apparent concomitant disease or drug intake. The screening characteristics of the participants are listed in Table 2.

[0046] Table 2: Subject demographics.

[0047]

[0048] placebo group (n=10) and (n=10) There were no statistically significant differences between subjects in the groups. On the day of screening, the average weight of all enrolled subjects was 59.3±4.64kg; the average height was 163.8±4.99cm, and the average BMI was 22.2±1.50Kg / m 2 .

[0049] Efficacy Assessment: Delayed Onset Muscle Soreness - Quality of life was analyzed throughout the study period as the primary efficacy measure. "p" values ​​indicate statistically significant changes in these symptoms between the placebo and active groups from baseline to final visit. Statistical analysis using analysis of covariance (ANCOVA) showed that the main efficacy parameter was statistically si...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a combination of digestive enzymes (Protease, Amylase, Lactase, Lipase, Cellulase) for the therapeutic management of delayed onset muscle soreness (DOMS).

Description

[0001] field of invention [0002] In general, the present invention relates to enzymes. More specifically, the present invention relates to the use of digestive enzymes for alleviating the symptoms of delayed onset muscle soreness (DOMS) [0003] Background of the invention [0004] Description of prior art [0005] Delayed onset muscle soreness (DOMS) is an exercise-induced phenomenon and is a recurring form of sports injury. It manifests as a feeling of discomfort, mainly to the skeletal muscles after unaccustomed physical activity. Associated symptoms include muscle shortening, increased passive stiffness, swelling, decreased strength and power, localized pain, and disturbed proprioception. This can even lead to structural damage to muscles and connective tissue, leading to changes in muscle function and joint mechanics that impair performance in track and field athletes and athletes. [0006] Treatment strategies for preventive and curative DOMS are well known in the a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/46A61K38/47A61K38/48
CPCA61K38/54C12Y302/01108C12Y301/01003C12Y302/01001C12Y302/01004A61P21/00A61P25/04A61P29/00
Inventor M.马吉德K.纳加布胡沙纳姆S.马吉德
Owner SAMI LABS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap